NASDAQ · Biotechnology

LGND (LGND) Stock

$293.15 -2.33% NASDAQ: LGND Healthcare

Valuation

MetricValue
Price$293.15
Market Cap$5.88B
P/E Ratio28.98
P/B Ratio4.46
P/S Ratio16.21
EPS (TTM)$7.66
52-Week High$323.23
52-Week Low$98.89
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE17.13%
ROA5.19%
ROCE4.62%
Gross Margin83.16%
Operating Margin33.58%
Net Margin55.95%
Debt/Equity0.45
Current Ratio21.28

Annual Financials (USD)

Metric20212022202320242025
Revenue$242.0M$196.0M$131.0M$167.0M$268.0M
Operating Profit$104.0M$3.0M$12.0M$-23.0M$47.0M
Net Profit$57.0M$-33.0M$52.0M$-4.0M$124.0M
EPS$3.34$-1.98$2.94$-0.22$6.13
Op Margin43.0%1.6%9.1%-13.5%17.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$763.0M$787.0M$942.0M$1.6B
Total Liabilities$476.0M$165.0M$86.0M$111.0M$543.0M
Cash$20.0M$45.0M$23.0M$72.0M$175.0M
Borrowings$324.0M$88.0M$6.0M$7.0M$451.0M

Latest News

Ligand Pharmaceuticals Insider Sold Shares Worth $1,566,377, According to a Recent SEC Filing MT Newswires · Jul 6, 2026 Ligand Pharmaceuticals Closes Offering of Senior Notes due 2031 MT Newswires · Jun 25, 2026 Ligand Announces Closing of Convertible Senior Notes Offering GlobeNewswire · Jun 25, 2026 Ligand Pharmaceuticals Prices Upsized $625 Million Convertible Notes Offering MT Newswires · Jun 23, 2026 Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering GlobeNewswire · Jun 23, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$79.0M$138.0M$50.0M$97.0M$49.0M
Investing Cash Flow$22.0M$146.0M$-66.0M$-163.0M$-378.0M
Financing Cash Flow$-26.0M$-15.0M$17.0M$60.0M$-25.0M
Net Cash Flow$-28.0M$25.0M$-22.0M$49.0M$103.0M
Free Cash Flow$70.0M$120.0M$-4.0M$77.0M$49.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.53
EV / EBITDA30.66
FCF Yield2.76%
Quick Ratio20.95
Interest Coverage—
Return 1Y116.46%
Return 3Y352.75%
Return 5Y300.48%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACAD $29.21 +2.67% 8.94 $5.00B 0.00%
ADMA $8.71 -0.91% 12.17 $2.02B 0.00%
BLTEBelite Bio, Inc $157.14 -2.45% -61.62 $6.30B 0.00%
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%
DYN $25.97 +2.89% -6.05 $4.85B 0.00%

About LGND

LGND stock trades at $293.15 with a market capitalization of $5.88B. The stock is valued at a price-to-earnings (P/E) ratio of 28.98, price-to-book of 4.46, price-to-sales of 16.21. Over the past 52 weeks the stock has ranged between $98.89 and $323.23, and currently trades 9.3% below its 52-week high.

On profitability, LGND generates a return on equity (ROE) of 17.13%, above the typical market average, return on capital employed of 4.62%, an operating margin of 33.58%, a net profit margin of 55.95%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides